ArticleNature communications2025
Photoenzymatic catalysis enables enantioselective radical dearomative spirocyclization.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dearomatization offers a powerful route towards three-dimensional spirocyclic architectures, which are pivotal in bioactive molecules and pharmaceuticals, particularly for enantioselective construction of congested quaternary spirocenters. However, biocatalytic dearomatization towards these attractive spirocyclic frameworks under mild and green conditions remain underexplored. Here, we report a photoenzymatic platform synergizing visible-light activation with engineered nicotinamide-dependent ketoreductase (KRED) catalysis to achieve highly enantioselective dearomative spirocyclization of N-hydroxyphthalimide esters. Semi-rational engineering of KRED P2-D12 enables the synthesis of diverse chiral spirocyclohexadienones, also including the challenging ortho-cyclohexadienones, with exceptional functional group tolerance and stereocontrol (up to >99% ee). The utility of this methodology is underscored significantly by the enantioselective total synthesis of the cytotoxic natural product (+)-denobilone A (93% ee). Overall, this work establishes a chemobiocatalytic platform for the synthesis of complex and chiral spiroarchitectures with high enantioselectivity, expanding the biocatalytic toolbox in sustainable synthetic chemistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.